
    
      In this open-label, single-center, head-to-head non-inferiority trial, treatment-naive or
      pegylated interferon treatment-experienced patients with GT1 infection were randomized to
      receive once-daily SOF 400 mg plus DCV 60 mg or SIM 150 mg for 12 weeks.
    
  